Department of Medical Chemistry, School of Pharmacy, Weifang Medical University, Weifang, Shandong, China.
Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China.
Biosci Trends. 2020 Jul 17;14(3):192-199. doi: 10.5582/bst.2020.01051. Epub 2020 May 9.
A series of 4-phenoxybenzenesulfonyl pyrrolidine derivatives were designed, synthesized, and evaluated as matrix metalloproteinases (MMPs) inhibitors. All of the synthesized compounds displayed inhibitory activity against MMP-2 and MMP-9. Compounds 4a, 4e, and 4i displayed more potent activity than the other compounds. While the three compounds mildly or moderately inhibited the proliferation of cancer cells, they significantly suppressed the migration and invasion of cancer cells at relatively low concentrations as determined by a wound healing assay and transwell assay. In addition, compound 4e suppressed vascular endothelial cell tube formation and sprouting of microvessels from aortic rings in vitro in a dose-dependent manner. Compound 4e markedly suppressed the pulmonary metastasis of H22 cells in mice. These findings along with molecular docking results suggested that compound 4e might be a promising candidate for further structural optimization to develop MMP inhibitors as potential anticancer agents.
一系列 4-苯氧基苯磺酰基吡咯烷衍生物被设计、合成并评估为基质金属蛋白酶 (MMPs) 抑制剂。所有合成的化合物均显示对 MMP-2 和 MMP-9 的抑制活性。化合物 4a、4e 和 4i 的活性比其他化合物更强。虽然这三种化合物对癌细胞的增殖有轻度或中度的抑制作用,但在划痕愈合试验和 Transwell 试验中,它们在相对较低的浓度下显著抑制癌细胞的迁移和侵袭。此外,化合物 4e 以剂量依赖的方式抑制了体外血管内皮细胞管形成和主动脉环中小血管的发芽。化合物 4e 显著抑制了小鼠 H22 细胞的肺转移。这些发现以及分子对接结果表明,化合物 4e 可能是进一步结构优化的有前途的候选物,以开发 MMP 抑制剂作为潜在的抗癌药物。